Welcome to our dedicated page for Galera Therapeutics news (Ticker: GRTX), a resource for investors and traders seeking the latest updates and insights on Galera Therapeutics stock.
Galera Therapeutics, Inc. (GRTX) generates news that reflects the evolution of a clinical-stage biopharmaceutical company navigating complex oncology development and corporate transitions. Company press releases cover clinical trial updates, FDA regulatory interactions, strategic reviews, financing events, corporate restructuring, acquisitions, and asset sales.
Historically, Galera’s news has focused on its superoxide dismutase mimetic programs, including avasopasem manganese for radiotherapy-induced and cisplatin-related toxicities and rucosopasem manganese for use with stereotactic body radiation therapy in non-small cell lung cancer and locally advanced pancreatic cancer. Updates have included the FDA’s acceptance and priority review of the avasopasem New Drug Application, issuance of a Complete Response Letter, scheduling and outcomes of a Type A meeting, and decisions to halt the GRECO-1 and GRECO-2 trials following a futility analysis.
Financial result announcements provide context on research and development spending, general and administrative expenses, net losses, and cash runway expectations, alongside descriptions of workforce reductions and cost-saving measures. These releases also describe the engagement of financial advisors and the Board’s evaluation of strategic alternatives aimed at maximizing stockholder value, including potential mergers, asset sales, licensing arrangements, or dissolution.
More recent news highlights major corporate events such as the Board’s approval of a Plan of Liquidation and Dissolution, the adoption of a limited duration stockholder rights agreement, the acquisition of Nova Pharmaceuticals, Inc., and the subsequent asset purchase agreement with Biossil Inc. for Galera’s dismutase mimetics portfolio. In parallel, Galera’s communications describe a shift toward a pan-nitric oxide synthase inhibitor program in advanced breast cancer.
Investors and observers can use the GRTX news feed to follow developments in Galera’s clinical programs, regulatory milestones, strategic transactions, and capital structure decisions over time.
Galera Therapeutics (Nasdaq: GRTX) announced that Mel Sorensen, M.D., CEO, will present at two investor conferences this November. The first event is the Jefferies London Healthcare Conference on November 18, 2021, available on-demand from 8:00 a.m. GMT. The second event is the Piper Sandler Annual Healthcare Conference on November 22, 2021, starting at 10 a.m. ET. Webcasts can be accessed from the investors.galeratx.com page and will be archived for 30 days.
Galera Therapeutics, Inc. (Nasdaq: GRTX) reported its Q3 2021 financial results, showcasing a net loss of $(22.6) million, or $(0.86) per share, compared to $(17.1) million, or $(0.69) per share in Q3 2020. The company maintains a solid cash position of $89 million, expected to last into 2023. Despite the Phase 3 ROMAN trial of avasopasem for severe oral mucositis not meeting its primary endpoint, it demonstrated tolerability and reduced severity duration. Enrollment continues in GRECO-1 and GRECO-2 trials for rucosopasem in lung and pancreatic cancers, with data expected in 2022.
Galera Therapeutics (GRTX) announced results from the Phase 3 ROMAN trial of avasopasem for severe oral mucositis (SOM) in head and neck cancer patients. The primary endpoint of reducing SOM incidence was not met, showing only a 16% reduction (54% vs. 64%) without statistical significance (p=0.113). However, secondary endpoints indicated a 56% reduction in duration of SOM (8 days vs. 18 days, p=0.011) and a 27% reduction in severity (Grade 4 OM). Avasopasem was well tolerated compared to placebo. The company continues to analyze results and explore next steps for its pipeline, including GC4711.
Galera Therapeutics, Inc. (Nasdaq: GRTX) has announced the appointments of Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer. Both executives bring over 25 years of experience in the biopharmaceutical industry. Bachleda, previously with Bristol Myers Squibb, will focus on the commercialization of avasopasem, a treatment for severe oral mucositis in cancer patients. Stacey, formerly at The Wistar Institute, will lead legal and compliance efforts. These hires come as Galera aims to transition into a commercial-stage company.
Galera Therapeutics (Nasdaq: GRTX) announced a virtual Key Opinion Leader event to discuss radiotherapy-induced severe oral mucositis (SOM) in head and neck cancer patients. The event is scheduled for Thursday, September 23, 2021, at 11:00 a.m. ET, featuring Dr. Carryn Anderson from the University of Iowa, alongside testimonials from survivors and insights from Galera's CEO, Mel Sorensen, M.D. The company’s lead candidate, avasopasem manganese, is in a Phase 3 ROMAN trial, expected to report results in the fourth quarter of 2021. The event will be accessible via Galera’s investor website.
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced promising results from its Phase 1/2 trial evaluating GC4419 in patients with locally advanced pancreatic cancer. The study showed significant improvements in overall survival (HR=0.48), progression-free survival (HR=0.46), local tumor control (HR=0.30), and time to distant metastasis (HR=0.39). Notably, 46% of patients treated with GC4419 were alive at last follow-up compared to 33% in the placebo group. The trial's positive outcomes support the ongoing GRECO-2 Phase 2b trial, which aims to further assess GC4711's efficacy.
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company, announced that Mel Sorensen, M.D., will present at three virtual investor conferences in September 2021. The events include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, and the Cantor Fitzgerald Global Healthcare Conference on September 29. Live webcasts will be available on Galera's Investors page, with archived versions accessible for 30 days thereafter.
Galera Therapeutics (GRTX) announced the completion of enrollment in its pivotal Phase 3 ROMAN trial for avasopasem, aimed at treating severe oral mucositis in head and neck cancer patients, with topline data expected in Q4 2021. An interim analysis of a 42-patient pancreatic cancer trial showed nearly doubled median overall survival (20.1 months) compared to placebo (10.9 months). Additionally, the company initiated the GRECO-2 trial for pancreatic cancer. Financial results for Q2 2021 included a net loss of $22.4 million and total assets of $115.3 million, boosted by $57.5 million in milestone payments from Blackstone Life Sciences.
Galera Therapeutics (GRTX) announced the completion of enrollment in its pivotal Phase 3 ROMAN trial for avasopasem, aimed at treating severe oral mucositis (SOM) in head and neck cancer patients undergoing radiotherapy. This milestone triggers a $37.5 million payment from Blackstone Life Sciences. Approximately 70% of patients receiving radiotherapy for head and neck cancer develop SOM, and there are currently no approved treatments. Topline data is expected in the second half of 2021, with the potential for regulatory approval and commercialization.
Galera Therapeutics (Nasdaq: GRTX) announced that CEO Mel Sorensen will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. ET. A live webcast will be available on Galera's Investors page, with an archived version accessible for 30 days post-event. Galera is focused on developing innovative therapeutics for cancer treatment, with lead candidate avasopasem manganese aimed at reducing radiation-induced severe oral mucositis. The company has multiple ongoing clinical trials and received FDA Fast Track and Breakthrough Therapy designations for avasopasem.